Coverage of this stock is exceptionally thin. Based on publicly available data, only one firm, H.C. Wainwright, maintains a current, attributable price objective: analyst Amit Dayal reiterated a Buy rating with a $10 target in a report dated August 8, 2025, when shares closed near $5.39. Because there is effectively only one covering analyst, there is no meaningful multi-analyst average or consensus range to calculate. Accordingly, this article treats $10 as a publicly discussed price objective rather than an analyst consensus, and investors should not read it as the collective view of the sell side. An earlier, lower $3.50 target from the same firm (mid-2024) illustrates how volatile and uncertain the outlook has been. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
With shares near $0.72, moving to $10 would represent an increase of roughly 1,290% (about 13.9 times the current price). That is not merely a substantial move; it is an extraordinary one. Importantly, the $10 target was published when shares traded far higher and before much of the subsequent price erosion, which means the implied distance has widened considerably. Reaching such a level would require not just improving fundamentals but a fundamental re-rating of a company that currently generates only a few hundred thousand dollars of quarterly revenue.
The company's operational story has shown genuine progress. In the second quarter of 2025, SenesTech reported record quarterly revenue of about $625,000, up 36% year over year, and a record gross margin of 65.4%. Evolve products, which accounted for roughly 83% of revenue, grew about 94% year over year. The analyst's thesis emphasized e-commerce expansion—more than half of third-quarter 2025 revenue came from online channels—supported by partnerships with major retailers including Amazon, Walmart and Home Depot.com, which the company has described as potential on-ramps to physical retail placement. Municipal pilot programs in major U.S. cities and a completed move to a new Phoenix-area manufacturing facility were also cited as potential growth drivers. From what I see, tracking these retail expansions closely remains important.
The obstacles are substantial and structural. The company remains deeply unprofitable, with a second-quarter 2025 net loss of about $1.6 million against revenue of $625,000, and it has relied on repeated at-the-market equity offerings to fund operations. Continued share issuance dilutes existing holders and has contributed to a dramatic decline in the share price and market capitalization. The 2024 reverse split signals past distress, and a sub-$1 stock price carries ongoing risk of further corporate actions. For a company of this size, even modest setbacks in a retail partnership, a slower municipal rollout, or a liquidity shortfall can have outsized effects on the share price.
Analyst price targets generally reflect a forward research horizon, often around 12 months, but no specific horizon beyond the August 2025 report has been clearly published for SNES, and that target predates significant subsequent price movement. Investors should monitor quarterly revenue growth and gross-margin trends, the pace and terms of any additional ATM share sales, cash runway, retail-channel expansion progress, municipal contract wins, and any regulatory developments for rodent-control products. Given the single-analyst coverage, any rating or target change from H.C. Wainwright would carry disproportionate weight. I’m watching this closely as dilution trends evolve.
SNES at $10 is a single-analyst objective, not a verified consensus, and it now sits at an enormous distance—roughly 1,290%—above the latest price near $0.72. The company's improving revenue, gross margins, and retail partnerships are real, but they are measured against persistent losses, aggressive dilution, and a reverse-split history that has repeatedly punished shareholders. The path to $10 would demand a combination of sustained revenue acceleration, a credible move toward profitability, and an end to dilutive financing—outcomes that are far from assured. Investors should treat the target as one firm's aspirational view and weigh it against the company's continuing capital needs and extreme share-price risk.
In my research process, I often turn to Tickeron’s AI Daily Buy/Sell Signals to help track rapidly changing conditions in volatile names like this one. The tool uses artificial intelligence to monitor thousands of stocks and generate Buy, Sell, or Hold signals based on technical behavior and market shifts, serving as a useful input alongside fundamental analysis without replacing it.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
The Moving Average Convergence Divergence (MACD) for SNES turned positive on October 02, 2026. Looking at past instances where SNES's MACD turned positive, the stock continued to rise in 39 of 47 cases over the following month. The odds of a continued upward trend are 83%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SNES's RSI Indicator exited the oversold zone, 38 of 51 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
Following a +24.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNES advanced for three days, in 152 of 202 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
SNES may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 29 of 32 cases where SNES's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on October 07, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SNES as a result. In 74 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNES declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for SNES entered a downward trend on October 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.567) is normal, around the industry mean (6.363). P/E Ratio (0.019) is within average values for comparable stocks, (209.940). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.548). Dividend Yield (0.000) settles around the average of (0.013) among similar stocks. P/S Ratio (1.832) is also within normal values, averaging (48.960).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. SNES’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNES’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a biotech platform and research company
Industry ChemicalsSpecialty